Madrigal Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Director or officer changeAug 12 →InsidersNo open-market buys. 9 insiders sold $73.5M, 146 of 167 sales on a 10b5-1 plan.→HoldersBaker Bros 9.3%RTW Investments 8.6%Jupiter Topco 8.4%→PeersClosest companies: AXSM, RIGL, ALT→
From the filings
Figures
- Revenue
- $1.28Blast 12 months
- Net income
- −$325.1Mlast 12 months
- Operating cash flow
- −$268.1Mlast 12 months
- Cash and equivalents
- $292.7Mat the last balance sheet
- Total debt
- $340.8Mat the last balance sheet
- Shares outstanding
- 23.1M shareson issue